Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 2, Pages 271
Publisher
MDPI AG
Online
2021-01-14
DOI
10.3390/cancers13020271
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prospects and Challenges for Use of CAR T Cell Therapies in Solid Tumors
- (2020) Sneha Ramakrishna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm
- (2020) Elodie Bôle-Richard et al. LEUKEMIA
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
- (2020) Alyssa Sheih et al. Nature Communications
- Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
- (2020) Sai Arun Batra et al. Cancer Immunology Research
- Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials
- (2020) Donghua Shi et al. CLINICAL CANCER RESEARCH
- Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
- (2020) Sonia Guedan et al. JOURNAL OF CLINICAL INVESTIGATION
- Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
- (2020) Jesus G. Berdeja et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
- (2020) Leila Jafarzadeh et al. Frontiers in Immunology
- Chimeric antigen receptor signaling: Functional consequences and design implications
- (2020) S. E. Lindner et al. Science Advances
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7
- (2020) Christina Amatya et al. MOLECULAR THERAPY
- How I treat adverse effects of CAR-T cell therapy
- (2020) Lucrecia Yáñez et al. ESMO Open
- Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
- (2020) Xue Li et al. MOLECULAR THERAPY
- Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY‑ESO‑1 and MAGE‑A4 in high‑grade soft‑tissue sarcoma
- (2019) Takuya Kakimoto et al. Oncology Letters
- Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma
- (2019) Ying Liu et al. JOURNAL OF IMMUNOLOGY
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma
- (2019) Philippe Rochigneux et al. OncoImmunology
- Next-Generation Cancer Immunotherapy Targeting Glypican-3
- (2019) Yasuhiro Shimizu et al. Frontiers in Oncology
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
- (2019) Ru Zhou et al. Frontiers in Immunology
- Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation
- (2019) Iva Xhangolli et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
- (2019) Sara Ghorashian et al. NATURE MEDICINE
- Eradication of Hepatocellular Carcinoma by NKG2D-Specific CAR-T Cells
- (2019) Bin Sun et al. Cancer Immunology Research
- Development of adaptive immune effector therapies in solid tumors
- (2019) P Comoli et al. ANNALS OF ONCOLOGY
- Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- (2019) Ibrahim Yakoub-Agha et al. HAEMATOLOGICA
- NY-ESO-1 expression in solid tumors predicts prognosis
- (2019) Huiyu Wang et al. MEDICINE
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma
- (2019) Zi Mei et al. Cancer Medicine
- Immune Responses in the Liver
- (2018) Paul Kubes et al. Annual Review of Immunology
- MAGE-A antigens as targets for cancer immunotherapy
- (2018) Erik Schooten et al. CANCER TREATMENT REVIEWS
- From clinical proof-of-concept to commercialization of CAR T cells
- (2018) Boris Calmels et al. DRUG DISCOVERY TODAY
- Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy
- (2018) Wei Zhu et al. HEPATOLOGY
- Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers
- (2018) Ashwini Raghavendra et al. HISTOPATHOLOGY
- Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide
- (2018) Delphine Maucort-Boulch et al. INTERNATIONAL JOURNAL OF CANCER
- Targets for immunotherapy of liver cancer
- (2018) Tim F. Greten et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- CAR-T cells: the long and winding road to solid tumors
- (2018) Maria Michela D’Aloia et al. Cell Death & Disease
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tuning T cell receptor affinity to optimize clinical risk-benefit when targeting α-fetoprotein-positive liver cancer
- (2018) Roslin Y. Docta et al. HEPATOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity
- (2017) Wenpeng Li et al. HUMAN GENE THERAPY
- High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma
- (2017) Youping Wei et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- An oxygen sensitive self-decision making engineered CAR T-cell
- (2017) Alexandre Juillerat et al. Scientific Reports
- Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
- (2017) Zhiwu Jiang et al. Frontiers in Immunology
- Prospects for combined use of oncolytic viruses and CAR T-cells
- (2017) Adam Ajina et al. Journal for ImmunoTherapy of Cancer
- Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
- (2017) Spencer Park et al. Scientific Reports
- The integrin αvβ6: a novel target for CAR T-cell immunotherapy?
- (2016) Lynsey M. Whilding et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors
- (2016) Timothy T. Spear et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prolonging CART Cell Persistence Using Conditioning with 5-Azacytidine
- (2016) A. Dolnikov et al. CYTOTHERAPY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T-cell therapy for solid tumors
- (2016) Kheng Newick et al. Molecular Therapy-Oncolytics
- Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area
- (2015) K Sideras et al. BRITISH JOURNAL OF CANCER
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
- (2015) X. Liu et al. CANCER RESEARCH
- Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient
- (2015) Waseem Qasim et al. JOURNAL OF HEPATOLOGY
- Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity
- (2015) Maarten A. Ligtenberg et al. JOURNAL OF IMMUNOLOGY
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- (2015) D Sommermeyer et al. LEUKEMIA
- Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy
- (2015) Hirofumi Hanaoka et al. MOLECULAR PHARMACEUTICS
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice
- (2013) Karin Krebs et al. GASTROENTEROLOGY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
- (2013) L.-C. S. Wang et al. Cancer Immunology Research
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
- (2013) Zakaria Grada et al. Molecular Therapy-Nucleic Acids
- A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus
- (2013) Sarene Koh et al. Molecular Therapy-Nucleic Acids
- Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma
- (2012) J. R. L. Maggs et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
- (2010) Maria R Parkhurst et al. MOLECULAR THERAPY
- The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
- (2009) M. Munz et al. CANCER RESEARCH
- EpCAM and -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
- (2008) T. Yamashita et al. CANCER RESEARCH
- CD44 and EpCAM: Cancer-Initiating Cell Markers
- (2008) Rachid Marhaba et al. CURRENT MOLECULAR MEDICINE
- T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes
- (2008) Felix Bohne et al. GASTROENTEROLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started